The research activity of the group is dedicated to the identification and characterization of new biologically active compounds. The inter-disciplinary approach is the driving force of the research activity which is focused on the design, synthesis and analysis of new focused compound libraries and on the preparation and characterization of chiral compounds. The group has prepared more than 1000 molecules (both natural and synthetic compounds) with drug-like properties. The biological investigations are carried out with several international collaborations.
Our laboratory is located at the Department of Drug Science of the University of Pavia
- The registration for the II level master in ‘Progettazione e Sviluppo dei Farmaci’ for the years 20-21 are OPEN!!!
For more information, please visit the PSF Master Website
- The registration for the II level master in ‘Progettazione e Sviluppo dei Farmaci’ for the years 20-21 are OPEN!!!For more information, please visit the PSF Master Website
- Setup and validation of a reliable docking protocol for the development of neuroprotective agents by targeting the Sigma-1 receptor (S1R)Rossino, G., Rui, M., Pozzetti, L., Schepmann, D., Wünsch, B., Zambieri, D, Pellavio, G., Laforenza, U., Rinaldi, S., Colombo, G., Morelli, L., Linciano, P., Rossi, D., Collina, S. Int. J. Mol. Sci. 2020. ABSTRACT. Sigma-1 receptor (S1R) is a promising molecular target for the development of novel effective therapies against neurodegenerative diseases. To speed up the discovery of new S1R modulators, herein we
- Tackling antimicrobial resistance with small-molecules targeting LsrK: challenges and opportunitiesPasquale Linciano, Valeria Cavalloro, Emanuela Martino, Johannes Kirchmair, Roberta Listro, Daniela Rossi, Simona Collina J. Med. Chem., 2020 Antimicrobial resistance (AMR) is a growing threat to severe health and economic consequences. The available antibiotics are losing efficacy, and the hunt for alternative strategies is a priority. Quorum Sensing (QS) controls biofilm and virulence factors production. Thus, the quenching of QS to
- Patent of the University of Pavia selected for the event Biovaria, Munich 8-9 May 2019The patent “Use of arylalkanolamines as sigma-1 receptor antagonists” (EP 3 113 768 B1) of the MedChemLab has been selected for the event BioVaria. BioVaria targets technology scouts, business developers and investors highlighting commercially attractive licensing opportunities and promising startups from across Europe. The Advisory Board selected the technology Treatment of neuropathic pain (Simona Collina, Daniela Rossi, Annamaria Marra, Marco